Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate-Reference-Cited by-同舟云学术

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

Published:2013-11-06 Issue:3 Volume:41 Page:505-510
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Sabet Amir,Ezziddin Khaled,Pape Ulrich-Frank,Reichman Karl,Haslerud Torjan,Ahmadzadehfar Hojjat,Biersack Hans-Jürgen,Nagarajah James,Ezziddin Samer

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-013-2601-x.pdf

Reference35 articles.

1. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010;40(2):78–88. doi: 10.1053/j.semnuclmed.2009.10.004 .

2. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26(13):2124–30. doi: 10.1200/JCO.2007.15.2553 .

3. Kwekkeboom DJ, de Herder WW, Krenning EP. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40(1):173–85, ix. doi: 10.1016/j.ecl.2010.12.003 .

4. Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003;44(1):1–6.

5. Delpassand ES, Samarghandi A, Mourtada JS, Zamanian S, Espenan GD, Sharif R, et al. Long-term survival, toxicity profile, and role of F-18 FDG PET/CT scan in patients with progressive neuroendocrine tumors following peptide receptor radionuclide therapy with high activity In-111 pentetreotide. Theranostics 2012;2(5):472–80. doi: 10.7150/thno.3739 .

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative SPECT/CT Metrics in Early Prediction of [¹⁷⁷Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients;Journal of Nuclear Medicine;2024-09-12

2. Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX;Chemical Science;2024

3. Role of Functional SPECT and PET in Renal Emergencies;Seminars in Nuclear Medicine;2023-11

4. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides;Chemical Reviews;2023-10-05

5. Non-invasive estimation of split renal function from routine 68Ga-SSR-PET/CT scans;Frontiers in Medicine;2023-06-28